SAN DIEGO, CA – February 19, 2015 – Pathway Genomics Corporation, a CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, announced it has named Anja Kammesheidt, Ph.D., as its vice president of research and development. Based at Pathway Genomics’ San Diego headquarters, Dr. Kammesheidt brings more than 15 years of experience to the role.
“We are honored to have Dr. Kammesheidt join our organization where she will oversee all assay development activities,” said Jim Plante, Pathway Genomics’ founder and CEO. “We know that her wealth of knowledge will be a major asset to the company and a vital component of reaching our commercial objectives as we move forward.”
Dr. Kammesheidt joined the molecular diagnostics space in 2002, serving as chief scientific officer at Ambry Genetics for a 10-year period. She then focused on oncology, working on genomics-based personalized diagnostics at Agendia (Irvine USA and Amsterdam NL), where she was also directing translational science projects. Dr. Kammesheidt joined Pathway Genomics in February 2015 as the vice president of research and development where she oversees all assay development activities.
“I aim to help drive the core of Pathway’s mission, which is to provide actionable and accurate genetic testing results to our valued clients,” said Dr. Kammesheidt.
Dr. Kammesheidt received her bachelor and doctoral degrees in biological sciences from the University of California, Irvine, with a focus on molecular neurobiology. Her early research interests centered on Alzheimer’s disease models and viral vector gene transfer systems. After completing her postdoctoral training at the University of California, San Diego, where she studied protein-targeting mechanisms at the neuromuscular junction, she joined Purdue Pharma as a research scientist working on neuropathic pain targets.
About Pathway Genomics Corporation
As a CLIA and CAP accredited clinical laboratory based in San Diego, California, Pathway Genomics provides physicians and their patients with actionable and accurate genetic information to improve or maintain health and wellness. Since its founding in 2008, Pathway Genomics has become known for its dedication to innovation and commitment to medical responsibility – making it a leader in the commercial genetic testing industry. Pathway Genomics’ testing services cover a variety of conditions including cancer risk, cardiac health, inherited diseases, nutrition and exercise response, as well as drug response for specific medications including those used in pain management and mental health. For more about Pathway Genomics, visit www.pathway.com.